



# Clinical & dosing information

## Dose and administration

JARDIANCE® (empagliflozin) is simple to initiate at 10 mg dosing across all indications in adults.<sup>1</sup>



Once daily dosing, any  
time of day<sup>1</sup>



Swallow whole with water,  
with or without food<sup>1</sup>



No upper age limit\*<sup>1</sup>

JARDIANCE® is not recommended in severe hepatic impairment, should not be used in breastfeeding or type 1 diabetes, and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. JARDIANCE® should be avoided in pregnancy. Always refer to the SmPC before prescribing.

\*Caution should be exercised in patients for whom an empagliflozin-induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on anti-hypertensive therapy with a history of hypotension or patients aged 75 years and older.

### Dose recommendations based on eGFR (mL/min/1.73m³)

SGLT2i	Licensed indication	≥20	<20
JARDIANCE®	Insufficiently controlled Type 2 Diabetes (T2D)	Initiate and continue 10mg	Continue 10mg Do not initiate
	Chronic Kidney Disease (CKD)		
	Symptomatic Chronic Heart Failure (CHF)		


- **For T2D:** increase to 25mg if further glycaemic control is needed in those with eGFR ≥60mL/min/1.73m³.
- **In T2D:** The glucose lowering efficacy of JARDIANCE is reduced in patients with an eGFR <45mL/min/1.73m³ and likely absent in patients with an eGFR <30mL/min/1.73m³. Therefore, if eGFR falls below 45mL/min/1.73m³, additional glucose lowering treatment should be considered if needed.
- **In CKD:** In patients with eGFR between 60-90, JARDIANCE can be initiated if uACR >30 mg/mmol.

## Safety information

## Mechanism of action

Sodium-glucose cotransporter 2 (SGLT2) is highly expressed in the kidney.<sup>1</sup> By blocking reuptake of glucose and sodium in the kidneys, SGLT2 inhibitors increase the excretion of both in the urine.<sup>1</sup>

SGLT2 inhibitors have multiple effects on metabolism and fluid balance in the Cardio-Renal-Metabolic (CRM) interconnected system.<sup>1</sup>



### Glycosuria

... which lowers plasma glucose, therefore reduces glycated haemoglobin (HbA1c) and glucose toxicity<sup>2</sup>

... which causes a caloric loss, resulting in weight loss<sup>1,3</sup> and reduction in fat mass<sup>1,4</sup>

### Osmotic diuresis

... which reduces plasma volume, leading to reduction in blood pressure and cardiac preload<sup>1,5</sup>

### Natriuresis


... which alters tubular-glomerular feedback and reduces glomerular hyperfiltration<sup>6</sup>

... which reduces arterial pressure,<sup>7</sup> leading to an improvement in cardiac afterload<sup>5</sup>

JARDIANCE® (empagliflozin) is a reversible, highly potent and selective competitive inhibitor of SGLT2.<sup>1</sup>

In addition to glucose lowering, JARDIANCE® (empagliflozin) demonstrated secondary benefits of reduction in weight and blood pressure in clinical trials although it is not licensed for this.<sup>7</sup>

### SGLT2 inhibitors: mechanism of action<sup>8</sup>



## Learn more about JARDIANCE® for:



### Type 2 diabetes (T2D)

Explore T2D >



### Chronic kidney disease (CKD)

Explore CKD >



### Symptomatic chronic heart failure (CHF)

Explore CHF >

## GET IN TOUCH

If you have any questions or would like to speak to a Boehringer Ingelheim representative, please contact us.

Contact us

Subscribe for updates

### Abbreviations

CHF: chronic heart failure; CKD: chronic kidney failure; CRM: cardio-renal-metabolic; CV: cardiovascular; eGFR: estimated glomerular filtration rate; HbA1c: glycated haemoglobin; LV: left ventricular; SGLT2: sodium-glucose co-transporter-2 inhibitor; T2D: type 2 diabetes mellitus.

### References

PC-GB-110622 | December 2024

### Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on [0800 328 1627](tel:08003281627) (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

## Indications

JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes<sup>1</sup>

JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.<sup>1</sup>

JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.<sup>1</sup>

## Disclaimer

The content on this website is in relation to adult patients.

Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.

Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.

1. JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at: <http://www.medicines.org.uk/emc/medicine/28973>.

PC-GB-109995 V4 | October 2025

Home > Products > JARDIANCE® (empagliflozin) > Clinical and dosing information